Our Science

Filter Science by Keyword

Filter science by  modality  Clear filters

Publication
Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology
Published in Clinical Pharmacology & Therapeutics
Disease Area
  • Oncology
Modality
  • Bispecific
View Details
Collaboration
Webinar
Translational Modeling Strategies to Predict Clinical Doses for CD3 Bispecific Molecules
Collaboration with Pfizer - Presented by Alison Betts, Applied BioMath
Disease Area
  • Oncology
Modality
  • Bispecific
View Details
Collaboration
Webinar
QSP Modeling for Dual Targeting Approaches for Two Immuno-oncology Therapeutics
Collaboration with Jounce - Presented by Dr. John M. Burke, Applied BioMath
Disease Area
  • Immuno-oncology
Modality
  • Bispecific
View Details
Publication
Mechanistic PKPD Models of Protein Therapeutics for Early Clinical Development
Published in AAPS Newsmagazine
Disease Area
  • Multiple
Modality
  • Multiple
View Details
Collaboration
Poster
QSP Approaches Accelerate a PD-1 x TIM-3 Therapeutic in Immuno-oncology
Collaboration with Jounce
Disease Area
  • Immuno-oncology
Modality
  • Bispecific
View Details
Collaboration
Poster
Non-clinical Studies to Clinical Design Using QSP Model of T Cell Engaging Bispecifics
Collaboration with Pfizer - Presented at AAPS 2019 PharmSci 360
Disease Area
  • Oncology
Modality
  • Bispecific
View Details
Collaboration
Webinar
Model-Based Approach to Design Bi-Specific Modalities in Early Discovery
Collaboration with Sanofi - Presented by Dr. Jennifer Fretland, Sanofi
Disease Area
  • Inflammation and Immunology
Modality
  • Bispecific
View Details
Publication
Model Firsts: How QSP can Pick the Right Dose for First-in-Human Trials
Published in BioCentury Innovations
Disease Area
  • Multiple
Modality
  • Multiple
View Details
Case Study
Early Feasibility Assessment
Disease Area
  • Multiple
Modality
  • Bispecific
View Details
Collaboration
Case Study
Predicting Optimal Drug Parameters and Doses
Collaboration with Jounce
Disease Area
  • Immuno-oncology
Modality
  • Bispecific
View Details